Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Puverel

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaRobert Chen, Alex F Herrera, Jessie Hou, et al.
The Lancet. Haematology|November 20, 2022
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trialAlex F Herrera, Lu Chen, Yago Nieto, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Haematologica|July 20, 2023
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphomaJames Godfrey, Matthew Mei, Lu Chen, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaRobert Chen, Alex F Herrera, Jessie Hou, et al.
The Lancet. Haematology|November 20, 2022
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trialAlex F Herrera, Lu Chen, Yago Nieto, et al.
Pageof 2